Document Detail

The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: a meta-analysis.
MedLine Citation:
PMID:  23195005     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: The objective of this study was to compare efficacy and safety of alemtuzumab, antithymocyte globulin (ATG), and daclizumab for induction therapy in organ transplantation.
METHODS: We searched PUBMED, EMBASE, and Cochrane databases to identify randomized controlled trials that compared alemtzumab, ATG, and daclizumab for induction therapy in kidney as well as pancreas transplantation. According to the inclusion criteria, the collected data included general characteristics of the studies and their major outcomes. The meta-analysis was performed using RevMan 5.0.25 software.
RESULTS: We identified 9 studies involving 777 patients. No differences between alemtuzumab, daclizumab, and ATG were observed in terms of patient survival, graft survival, or acute rejection episodes at a 24-month follow-up (P = .62, P = .55, and P = .08, respectively). Infections within 36 months were greater between the alemtuzumab and the ATG group (P = .03). There was no significant difference in terms of infection at 24 months.
CONCLUSIONS: Alemtuzumab and daclizumab appeared to be as effective as ATG for induction therapy in kidney transplantation at a follow-up of 24 months. However, alemtuzumab showed a lower rate of infection at 36 months compared with ATG.
W-J Hao; H-T Zong; Y-S Cui; Y Zhang
Related Documents :
20826575 - The pathogenesis of cystinosis: mechanisms beyond cystine accumulation.
16870245 - Isolation and transplantation of spermatogonia in sheep.
23924935 - Everolimus-incorporated immunosuppressant strategy improves renal dysfunction while mai...
23842465 - Would you be a face transplant donor? a survey of the turkish population about face all...
17532965 - Effects of exogenous surfactant instillation in clinical lung transplantation: a prospe...
7906765 - Ultrasonic indicators of ureteric reflux in the newborn.
Publication Detail:
Type:  Journal Article; Meta-Analysis; Review    
Journal Detail:
Title:  Transplantation proceedings     Volume:  44     ISSN:  1873-2623     ISO Abbreviation:  Transplant. Proc.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-30     Completed Date:  2013-05-13     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  0243532     Medline TA:  Transplant Proc     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2955-60     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Urology Department, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Antibodies, Monoclonal, Humanized / adverse effects,  therapeutic use*
Antilymphocyte Serum / adverse effects,  therapeutic use*
Communicable Diseases / immunology
Drug Therapy, Combination
Graft Rejection / immunology,  mortality,  prevention & control*
Graft Survival / drug effects*
Immunoglobulin G / adverse effects,  therapeutic use*
Immunosuppressive Agents / adverse effects,  therapeutic use*
Kidney Transplantation / adverse effects,  immunology*,  mortality
Odds Ratio
Pancreas Transplantation / adverse effects,  immunology*,  mortality
Risk Factors
Time Factors
Transplantation Tolerance / drug effects
Treatment Outcome
Reg. No./Substance:
0/Antibodies, Monoclonal, Humanized; 0/Antilymphocyte Serum; 0/Immunoglobulin G; 0/Immunosuppressive Agents; 3A189DH42V/alemtuzumab; CUJ2MVI71Y/daclizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Combination of epidural anesthesia and general anesthesia attenuates stress response to renal transp...
Next Document:  High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroi...